摘要
目的：肺动脉高压是先天性心脏病较常见的严重继发性病变，是影响先心病外科治疗效果的重要因素。本文通过川芎嗪对先心病肺动脉高压围术期血浆中内皮依赖收缩因子及舒张因子变化的研究，探讨川芎嗪对肺血管内皮细胞的保护作用及对肺动脉压的影响。方法：随机选取安徽医科大学第一附属医院心血管外科手术治疗先天性心脏病45例。其中中、重度肺动脉高压30例；肺动脉压正常15例。肺动脉高压中随机分为川芎嗪治疗组(A组，n=15)及对照组(B组，n=15)。实验组手术前1周开始应用川芎嗪至手术后3日，静脉滴注盐酸川芎嗪注射液4-5 mg／kg／d(常州制药厂，40mg／支，生产批号0204002)。肺动脉压正常者为空白对照组(C组，n=15)。对照组及空白组不用川芎嗪，其它治疗用药一致。实验组于用药前，手术前1天，术后24h，术后72h；对照组于术前，术后24h，术后72h；空白组于术前，术后24h抽取静脉血，根据需要行抗凝、离心，分离出血浆，测定血浆中ET-1、NO、cAMP、cGMP含量。实验组于用药前及术中测定肺动脉压。结果：1．实验组及对照组各时点血浆ET-1含量明显高于空白组，NO、cAMP、cGMP含量明显低于空白组，差异均有显著性(P＜0.01)。2．实验组手术前1天肺动脉压较用药前降低，差异有显著性(P＜0.01)。用药前及手术前1天血浆ET-1含量与肺动脉压呈正相关(P＜0.01)。3．实验组手术前1天及术后72h血浆ET-1含量分别低于用药前及术后24h，NO、cAMP、cGMP含量分别高于用药前及术后24h，差异有显著性(P＜0.01)。4．实验组及对照组两组比较：用药前及术后24h血浆中各因子含量无明显变化(P＞0.05)。实验组术后72h血浆ET-1的含量明显下降，cGMP含量明显升高，差异有显著性(P＜0.01)。NO及cAMP含量无明显变化(P＞0.05)。结论：1．先心病肺动脉高压患者，血浆中ET-1含量明显升高，且与肺动脉压呈正相关，而NO、cAMP及cGMP含量明显降低。2．应用川
安徽医科大学硕士学位论文
芍嗦可明显降低血浆中ET一的含量，增加NO、cAMP及cGMP的含量，提示川芍嗦
可降低肺动脉张力及肺动脉压力，减少围术期肺动脉高压危象的发生率，提高手
术的成功率。
Objective: Pulmonary hypertension(PH) is a fairly common and serious leisure succeed to congenital heart disease .It is a important agent to affect surgical therapeutic efficacy . The article investigates changes of plasma levels of endothelium derived relaxing factor and endothelium derived contracting factor in congenital heart disease associated to pulmonary hypertension in perioperative period to study protect action of on endothelial cells of pneumoangiogram and influence of pulmonary artery pressure. Method: 30 patients finally diagnosed as congenital heart defects associated with moderate and severe PH were randomly divided into the Tetramethylpyrazine group (A group,n=15) and the control group (B group,n=15). 15 patients without PH were called the blank control group (C group,n=15).The patients of A group were injected with Tetramethylpyrazine(5mg/kg) from 1 week before operation to 3 days after operation. Venous blood samples were taken at the following times before medication , 1 day before operati
on ,24 hours and 72 hours after operation in A group. In B group venous blood samples were taken at preoperative period and 24 hours after operation. Venous blood samples were taken at the following times before operation,24 hours and 72 hours after operation in C group. We measure the pulmonary artery pressure (PAP) before medication and on operation in A group and the concentrations of endothelin-1 (ET-1),nitric oxide (NO),cAMP and cGMP in perioperative period. Results: The PAP of A group on operation were lower than before medication (P<0.01).It has been found that the patients' PAP is in postitive correlation with plasma ET-1 level. In both
A and B groups the concentration of ET-1 was higher than that in the C group (P< 0.01),but the concentrations of NO,cAMP and cGMP were lower than that in the C group(P<0.01). After treating PH with Tetramethylpyrazine, compared A and B group, plasma ET-1 level decrease and plasma NO,cAMP,cGMP levels increase and has significant difference before operation. Compared 24h with 72h after operation, plasma ET-1 level decrease and plasma cGMP levels increase and has significant difference. But plasma NO and cAMP levels has no transparent changes. Conclusion: Plasma ET-1 level increase obviously and is in positive correlation with PAP , but plasma NO ,cAMP and cGMP levels decrease obviously in congenital heart disease. After treating PH with Tetramethylpyrazine, plasma ET-1 level decrease and plasma NO,cAMP,cGMP levels increase . It prompt that Tetramethylpyrazine can reduce tension and pressure of pulmonary artery and has profitable of decreasing incidence of pulmonary hypertension crisis in perioperative period t
o rise the success rate of operation.
引文
1．尹黎波．继发性肺动脉高压诊断的一些进展．华西医学，1996；11(4)：423～6
2. Hynynen M, Sai jonmaa O, Tikkanen I, et al. Increased plasma endothelin immunoreactivity during cardiopulmonary bypass: a preliminary observation. J Thorac Cardiovasc Surg, 1992; 103(5): 1024-5
3. Knothe C, Boldt J, Zickmann B, et al. Endothelin plasma levels in old
and young patients during open heart surgery: correlations to cardiopulmonary and endocrinology parameters. J Thorac Cardiovasc Pharmacol. 1992; 20(4): 664-670
4. Hashimoto K, Miyamoto H, Suzuki K, et al. Evidence of organ damage after cardiopulmonary bypass. The role of elastase and vasoactive mediators. J Thorac Cardiovasc Surg, 1992; 104(3): 666-73.
5. Yamamoto K, Ikeda U, Mito H, et al. Endothelin production in pulmonary circulation of patients with mitral stenosis. Circulation, 1994; 89(5): 2093-8
6. Giald A, Yanagisawa M, Langleben D, et al. Expression of ET-1 in the lungs of patients with pulmonary hypertension. N Engl J Med, 1993; 328(24): 1732～9
7. Hiramatsu T, Imai Y, Takanashi Y, et al. Time course of endothelin-1 and nitric anion levels after cardiopulmonary bypass in congenital heart defects. Ann Thorac Surg, 1997; 63(3): 648-52
8. Reid LM. The Third Grover Conference on the pulmonary Circulation. The control of cellular proliferation in the pulmonary circulation[J]. Am Rev Respir Dis, 1989; 140(5): 1490～3
9．阮英茆．100例先天性心脏病肺动脉高压肺活检病理分级的初步探讨．中国循环杂志，1992；11：54～57
10．张运，主编．多普勒超声心动图学．第一版．山东：青岛出版社，1988；371-419
11．陈国伟，等主编．现代心脏内科学．长沙：湖南科技出版社．1991
12. Allen K, Haworth SG. Human postnatal pulmonary arterial remodeling. Ultrastructural studies of smooth muscle cell and connective tissue maturation. Lab Invest, 1988; 59(5): 702～9
13. Tozzi CA, Poiani GJ, Harangozo AM. et al. Pressure-induced connective tissue synthesis in pulmonary artery segments is dependent on intact
endothelium. J Clin Invest, 1989; 84(3): 1005～12
14．程显声，蔡如升．肺血管疾病学[M]．北京：北京医科大学协和医科大学联合出版社，1993：4
15. Palmer PM,Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature, 1987; 327(6122):524～6
16. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature, 1988; 332(6163): 411～5
17. Vane JR, Amgaard EE, Botting PM. Regulatory functions of the vascular endothelium. N Engl J Med, 1990; 323(1): 27～36
18. Yoshibayashi[6.Yoshibayashi M,Nighioka K,Nakao K,et al. Plasma endothelin concentrations in patients with pulmonary hypertension associated with congenital heart defects. Circulation, 1991; 84(6)2280～4
19. White GE. Gimbrone MA Jr, Fujiwara K. Factors influencing the expression of stress fibers in vascular endothelial cells in situ. J Cell Bio,1983;97(2):416～24
20. Giald A, Yanagisawa M,Langleben D, et al. Expression of ET-1 in the lungs of patients with pulmonary hypertension. N Engl J Med, 1993;328(24):1732～9
21. De Nucci G, Thomas R, D' Orleans JP. Pressor effects of circulating endothelium and limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium derived relaxing factor. Proc Nalt Acad Sci USA, 1988; 85: 9797
22. Celemajer DS, Cullen S, Deanfield JE, et al. Impaiment of endothelium-dependent pulmonary artery relaxation in children with
congenital heart disease and abnormal pulmonary hemodynamics. Circulation, 1993, 87(2): 440～6
23. Kidd L, Driscoll DJ, Gersony WM,et al. Second natural history study of congenital heart defects: Results of treatment of patients with ventricular septal defects. Circulation, 1993; 87(2 Supp1): Ⅰ38～51
24．程显声．常见合并症-肺动脉高压．见：朱晓东，主编．心脏外科指南．第一版．北京：世界图书出版公司出版，1991．153～7
25．汪曾炜．肺移植．见：汪曾炜，主编．手术学全集-心血管外科卷．第一版．北京人民军医出版社，1996．816～21
26. McLaughlin VV, Centhner DE, Panella M M, et al. Reduction in pulmonary vascular resistance with long-term epoprostenol(prostacyclin)therapy in primary pulmony hypertension[J].N Engl J Med, 1998;338(5): 273～7
27. Shapiro SM, Oudiz RJ, Cao T, et al. Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion[J]. J Am Coll Cardoil, 1997; 30(2): 343～9
28. Escudero[51. Estudero J, Navaiio J, Paduah, et al. Hemodynamic changes with enalapril in pulmonary aterial hypertension secondary to congenital heart disease[J]. Chest, 1987; 91(3):351
29. Zielinski J, Hawrylkiewicz I, Gorecka D, et al. Captopril effects on pulmonary and systemic hemodynamics in chronic cor pulmonale. Chest, 1986; 90(4): 562-5
30．李铁罗，谭秀娟．心脏手术病人围术期肺动脉高压治疗及其进展．《国外医学》麻醉学与复苏分册，1999；20(4)：219～223
31. Lunn RJ, Inhaled NO therapy. Mayo Clin Proc, 1995; 70(3): 247～55
32．楼雅卿，张宏，曹霞．磷酸川芎嗪在狗和大鼠的药代动力学和体内命运．
药学学报，1986，21(7)：481-487
33．王鸿祥．从血液流变学角度探讨川芎嗪治疗脑血栓形成的机理．河南医科大学学报．1986，2(2)：153
34．马金城，袁海涛，盛树力．内皮素-1 对大鼠血管平滑肌的作用及川芎嗪的对抗效果．中国药理学和毒理学杂志，1993，7(3)：170-172
35．邹爱平．扩血管药对大鼠急性缺氧性肺动脉高压的影响：川芎嗪、汉防己甲素、酚苄明及酚妥拉明的作用．武汉医学院学报，1984；13(4)：282～285．
36．陈柏好，王君健，程方，等．青霉胺和川芎嚷对大鼠低氧性肺动脉高压的影响．中华结核和呼吸杂志，1990：13(5)：268～270．
37．袁小剑．钙拮抗剂对大鼠急性低氧性肺动脉高压形成的影响．中国应用生理学杂志，1989；(2)：136～141．
38．严仪昭，陈祥银，孙仁宇，等．764-3和川芎嗪对低氧引起的肺外肺动脉羟脯氨酸含量的影响．中华结核和呼吸杂志，1996；19(4)：206～8
39．罗光．川芎嗪和山莨菪碱对兔全血粘度及红细胞变形性的影响．中华医学杂志，1987；67(11)：607～609．
40．戴爱国，张珍祥，牛汝楫，等．川芎嗪对大鼠慢性缺氧性肺动脉高压的保护作用及其NOS基因表达的关系[J]．中国药理学通报．1996；12(2)：130～3
41．林丽娜，王万铁，徐正祈，等．川芎嗪和山莨菪碱对兔全血粘度及红细胞变形性的影响．胃肠病学和肝病学杂志，1998；7(4)：314～316．
42．邱海波，潘家绮，杜斌，等．地塞米松，布洛芬和川芎嗪对脂多糖诱导TNFα产生的影响．中国药理学报，1997；18(1)：67-70
43. Kuchan MJ, Frangos JA. Shear stress regulates endothelin-1 release via protein kinase C and cGMP in cultural endothelial cells. Am J Physio, 1993;264(1 pt 2): H150～6
44. Engelman DJ, Watanabe M, Maulik N, et al.L-arginine reduces endothelial inflammation and myocardial stunning during ischemia/reperfusion[J].Ann Thorac Surg, 1995; 60(5): 1275～81
45. Komai H, Adatia IT, Elliott MJ, et al. Increased plasma levels of endothelin-1 after cardiopulmonary bypass in patients with pulmonary hypertension and congenital heart disease[J].J Thorac Cardiovasc Surg, 1993; 106(3): 473～8
46. Ikeda U, Yamamoto K, Maeda Y, et al. Endothelin-1 inhabits nitric oxide synthesis in vascular smooth muscle cells[J]. Hypertension, 1997; 29(1 pt 1): 65～9
47. Verhaar MC, Strachan Fe, Newby DE, et al. Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade[J]. Circulation, 1998; 97(8): 752～6
48. Kobinia GS, Laraia PJ, Dambra MN, et al. Effects of experimental cardiopulmonary bypass on systemic and transcardiac thromboxane B2 levels. J Thorac Cardiovasc Surg, 1986; 91: 852～857
49．龙村．体外循环中TXA2／PGI2的变化异常及其防治．中华胸心血管外科杂志．1993；9(1)；84～85，
50. Ellis EF, Roberts II LJ, Payne NA, et al. Coronary arterial smooth muscle contraction by a substance released from platelets: evidence that it is thromboxane A2. Science, 1976; 193: 1135～1137
51．安梅．再灌注性肺损伤．解放军医学杂志，1993；16(3)：233～235
52．石湘芸，姚松朝，杨晔，等．血管活性物质与临床．北京：北京医科大学、中国协和医科大学联合出版社，1992：234～239
53．蔡伟菁，龚兰生，丁怀翌，等．中药槲寄生、川芎嗪对体外人血管内皮细胞的影响．上海医学，1991；14(8)462～464．
54．丁克宏，梁念慈．川芎嗪对血小板肌醇磷和20K蛋白质磷酸化的抑制作用．中国药理学通报，1992；8(5)：377～379
55．钱有辉，高尚志，姚震，等．体外循环中丹参、别嘌岭、川芎嗪对氧自由基清除
作用．中华胸心外科杂志，1993；9(3)：224～226
56. Emori T, Hirata Y, Kanno K, et al. Endothelin-3 stimulates production of endothelium-derived nitric oxide via phosphoinositide breakdown. Biochem Biophys Res Commun, 1991; 174(1): 228～35
57. Visakorpi T. Proliferative activity determined by DNA flow cytometry and proliferative cell nuclear antigen(PCNA) immunohistochemistry as a prognostic carcinoma[J].J Enthol, 1992;168(1):7
58. Rabinovitch M, Haworth SG, Castaneda AR, et al. Lung biopsy in congenital heart disease: a morphometric approach to pulmonary vascular disease. Circulation, 1978; 58(6): 1107～22
59. White GE. Gimbrone MA Jr, Fujiwara K. Factors influencing the expression of stress fibers in vascular endothelial cells in situ. J Cell Bio, 1983; 97(2): 416～24
60. Deway CF JR, Bussolari SR, Gimbrone MA Jr, et al. The dynamic response of vascular endothelial cells to fluid shear stress. J Biomech Engl. 1981; 103(3): 177～85
61. Tozzi CA, Poiani GJ, Harangozo AM. et al. Pressure-induced connective tissue synthesis in pulmonary artery segments is dependent on intact endothelium. J Clin Invest, 1989;84(3):1005～12
62. Janakideve MK, Fisher P, Del Vecchio PJ, et al. endothelin-1 stimulates DNA synthesis and proliferation of pulmonary artery smooth muscle cells. Am J Physiol, 1992; 263(6 pt): C1～295
63．王良兴，喻林升，王群姬，等．川芎嗪对慢性低O2高CO2大鼠肺动脉结构型和诱导型一氧化氮合酶及其基因表达的影响．中国药理学通报，2000；16(1)：63～66
64. Karmazyn M, Ray M, Haist JV. Comparative effects of Na/H exchanger in hibitors against cardial injury prouced by ischemia/reperfusion
(hypoxia/reoxygenation) and the calcium paradox. J Cardiovasc pharmacol. 1993, 21; 172-178
65. Hil G, Eman N, Dse W. Regulation and deregulation of cardiac Na~+-Ca~(2+) exchange in giant excised sarcolemmal membrane patches. Nature 1990, 344: 242-245